Replies to post #602824 on NorthWest Biotherapeutics Inc (NWBO)

[Idunno]

Impressive work….

[aesop1]

Finally some sound logic in the tissue agnostic approvals.....yes they will require trials and confirmatory trials if using surrogates. All solid cancer ain't going to happen without trials. Sorry guys that isn't what the Cares act is about.

[hoffmann6383]

Thanks for sharing all of this info atl! Good work.

[dstock07734]

Great work! Thanks for sharing with us.

[JMarv]

Nice findings ATL! Thanks for sharing!

[Legend431]

Great findings however information breadcrumbed together from 2019 does nothing for the stock price. Also if it was material NWBO would have had to talk about it so it is coincidental in my book.

[CrashOverride]

Trillion-dollar technology.

[pqr]

ATL thanks. Very interesting.

[Truthfan]

A keeper, thank you ATLnsider.

Interesting read:
“Responding to urgency to address unmet biomedical needs and the aspiration to pursue only the most audacious and impactful programs at ARPA-H’s founding, I outlined an approach to effectively communicate critical mission focus areas for investment and orchestrate how ARPA-H will determine the specific programs to fund. To frame this critical answer for our stakeholders, we developed four ARPA- H focus areas: Health Science Futures, Scalable Solutions, Proactive Health, and Resilient Systems.

These focus areas align with key areas where we believe big investment from ARPA-H can significantly advance the state of the art and even change the course of a particular field in a disease agnostic manner.”
Renee D. Wegrzyn, PhD - ARPA-H 2024

https://arpa-h.gov/assets/files/ARPA-H_FY_2024.pdf

[ATLnsider]

I forgot to post the link to the FDA’s website, for Dr. Adnan Jaigirdar’s bio sketch. Please note the highlighted words in red, that are included in Dr. Jaigirdar’s FDA bio:

Adnan A. Jaigirdar
Medical Officer
CBER/FDA

Adnan Jaigirdar is a medical officer in Oncology in the Office of Tissues and Advanced Therapies (OTAT), in the Center for Biologics Evaluation and Review (CBER) at FDA. This office evaluates and approves innovative cancer therapeutics with curative potential. Dr. Jaigirdar focuses in the review of investigational biologic and combination advanced therapies involving cell and gene therapy in solid tumors. Examples include chimeric antigen receptor (CAR) T cells, dendritic cells, adoptive T therapies, tumor neoantigen based cell personalized medicine (vaccine or cell therapy), natural killer cells, oncolytic viruses, therapeutic cancer vaccines, and combinations of these immune therapeutics with checkpoint inhibitors and other agents.

https://www.fda.gov/media/124901/download

[CaptainObvious]

Great post, ATL.
Should the 5/10 presentation at NYAS be in that list?

[Mionaer1]

Great DD. Thanks ATL!

[eagle8]

Great, solid DD, ATL.
Thanks so much for sharing.

Best to you.

[jammy32]

2019. This will surely move the stock to 63 cents. Thanks

[Smitty5150]

These people are all inter-connected, whether they work for private or public entities. They hold sway over each other. Its just the way it is.

You are most likely correct, DCVax will probably receive Tissue Agnostic approval. I believe that is what they have been working on. Time will tell. If they do receive TA approval. There will be many rich investors...a mere $10,000 investment will be worth 10-15x that in less than week after such announcement.

Big Pharma knows this, make no mistake. And I stand by my claim that a partnership has probably been inked already, or very close. Time will tell. I personally think we are very, very close to a game-changing catalyst. The bears sure have been busy since last week.....they can "smell" it too. My guess is they lose their shirts if not shares are not covered soon.

[dennisdave]

so NWBO in its last 10Q was lying when it said this:

The Company has completed a Phase 3 clinical trial of its DCVax®-L product for glioblastoma braincancer , has publicly reported the results in a peer reviewed publication in a medical journal as well as at a medical conference, and is working on prerequisites and preparations for filing an application for regulatory approval of the product.

So in their last 10Q NWBO said they were working on preparations for filing an application for approval of the product FOR glioblastoma braincancer

But according to you thats nonsense in reality, they are working application to be approved on a Tissue Agnostic basis?

So they lied in their last 10Q?